• BetterLife Pharma formed a scientific advisory board, appointing Professor Peter Goadsby co-chair.
• The board will guide BETR-001 clinical development for chronic cluster headache and chronic migraine.
• Goadsby previously held faculty positions at University College London and the University of California, San Francisco.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.